Comprehensive Hereditary Cancer Panel
Use
The Comprehensive Hereditary Cancer Panel analyzes 94 genes that are linked to an elevated risk of various cancers. This test is typically recommended for patients with a significant family history of cancer or a personal history suggestive of hereditary cancer syndromes. It aids in confirming clinical diagnoses and assists in determining prognosis and family planning options. Patients identified at risk can consider targeted treatment options or participate in relevant clinical trials.
Special Instructions
Samples can be collected using several methods including blood in EDTA, extracted DNA, cultured skin fibroblast, buccal swab, saliva, and skin biopsy. Each sample type has specific collection, shipping, and storage instructions to ensure viability. We emphasize that samples should arrive in the lab within specified timeframes to avoid rejection.
Limitations
NGS may not detect all copy number changes due to factors such as sample quality or complexities introduced by pseudogenes. A negative result does not eliminate the possibility of undetected genetic anomalies. Additionally, alternative assays like MLPA or aCGH may be necessary for confirmation of any identified copy number changes.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
13 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood (Unknown)
Volume
3-5 cc
Minimum Volume
N/A
Container
EDTA (purple-top) tube
Collection Instructions
Draw blood in an EDTA (purple-top) tube(s).
Storage Instructions
Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze. Sample must arrive within 72 hours.
Causes for Rejection
Samples received in the lab greater than 30 days after date of collection will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | N/A |
| Refrigerated | N/A |
| Frozen | N/A |